Saturday, July 14, 2018 4:58:56 PM
The following conjectures are of no importance regarding any investment in AVXL securities, or near-term share prices of such. Offered are merely conjectures of how long patients taking Anavex 2-73 (once approved by the FDA) might be taking the drug.
Conventional perspectives would presume that once diagnosed with a central nervous system disease or condition allowed to be treated by Anavex 2-73 by the FDA, such treatment, such dosing, would be continuous, without interruption or termination.
This is reasonable, considering the targeted CNS diseases. All of them are chronic (continuing) in duration. Therefore, treatment dosings, once started, would be presumed to be likewise chronic, continuing.
In the case of Alzheimer’s, it could be reasonably presumed that Anavex 2-73 dosings, once started, will need to be continued, without interruption. The disease persists; therefore continuing treatment will be required. Understandable, unless....
Unless Anavex 2-73 not only temporally (for a time) restores normalized neuron function, but also restores normalized neuron architecture and biochemical function. It is already known that a primary mechanism of action of Anavex 2-73 is to more functionally reconnect endoplasmic reticula with their associated, energy-supplying mitochondria, thereby allowing normalized protein folding. Properly folded proteins, in most cases, are functioning enzymes, which control normalized cell chemical pathways. Normalized cellular function and health result.
Here’s the yet unanswered question. If dissembled endoplasmic reticula and their associated mitochondria are chemically re-connected by the Anavex sigma-1 receptor agonist, allowing restored, normalized enzyme production, how long do those re-connections last? Do both of those organelles rather quickly dis-connect upon the immediate absence of the Anavex molecule; or, does the molecule cause a more permanent, lasting re-connection?
It is not unreasonable for a more permanent, lasting re-connection to occur. It can take many years, even decades, for the endoplasmic reticula to disconnect from the mitochondria. Alzheimer’s, except for a few, rare genetic forms, seldom occurs until subjects are at least in their forties or fifties. Sixties and seventies are more common ages of typical Alzheimer’s onset. For all of those earlier years, neuron organelles remained functionally intact.
Therefore, if Anavex 2-73 re-connects them, will they quickly dis-connect in the absence of the drug; or will the restoration of normalized neuron architecture — properly connected ERs with mitochondria — continue for substantial periods of time? That might, indeed, prove to be the case. After a few months, say, of Anavex 2-73 dosing (at optimized levels), restored neuron functions may well persist, with no continuing need for the presence of sigma-1 receptor agonists.
How well will those organelles remain connected? Will Alzheimer’s patients have to take persisting doses of Anavex 2-73 chronically? Or, for shorter, defined start-of-treatment periods only?
Perhaps treatment will require ample start-of-treatment dosings, then tailored down to smaller chronic maintenance doses.
Conversely, will effective prophylactic (preventional) dosings be very small, before any gross, frank symptoms appear? Will small initial dosings prevent either the onset or the progression of Alzheimer’s, if started early enough?
None of this can be presently known; will need extensive clinical determinations.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM